MR
Therapeutic Areas
Ardelyx Pipeline
| Drug | Indication | Phase |
|---|---|---|
| XPHOZAH (tenapanor) | Control of serum phosphorus in chronic kidney disease on dialysis | Approved |
| IBSRELA (tenapanor) | Irritable Bowel Syndrome with Constipation (IBS-C) | Approved |
| Tenapanor | Hyperphosphatemia in CKD patients not on dialysis | Phase 2 |
| Next-Gen NHE3 Inhibitors / Pipeline Candidates | Undisclosed cardiorenal, metabolic, GI indications | Discovery/Preclinical |
Leadership Team at Ardelyx
SH
Sue Hohenleitner
Chief Financial Officer
EF
Eric Foster
Chief Commercial Officer
RD
Rajani Dinavahi
Chief Medical Officer
EG
Elizabeth Grammer
Chief Legal & Administrative Officer
JB
John Bishop
Chief Technical and Quality Officer
LW
Laura Williams
Chief Patient Officer
MK
Mike Kelliher
Chief Business Officer
JB
Jamie Brady
Chief Human Resources Officer
DM
David Mott
Chairman of the Board
RB
Robert Bazemore
Director